WO2012138911A3 - Conjugates of anti-hiv drugs and somatostatin analogs - Google Patents

Conjugates of anti-hiv drugs and somatostatin analogs Download PDF

Info

Publication number
WO2012138911A3
WO2012138911A3 PCT/US2012/032402 US2012032402W WO2012138911A3 WO 2012138911 A3 WO2012138911 A3 WO 2012138911A3 US 2012032402 W US2012032402 W US 2012032402W WO 2012138911 A3 WO2012138911 A3 WO 2012138911A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
somatostatin analogs
hiv drugs
hiv
somatostatin
Prior art date
Application number
PCT/US2012/032402
Other languages
French (fr)
Other versions
WO2012138911A2 (en
Inventor
Debasis MONDAL
Christine BULOT
Joseph Fuselier
David Coy
Original Assignee
The Administrators Of The Tulane Educational Fund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Administrators Of The Tulane Educational Fund filed Critical The Administrators Of The Tulane Educational Fund
Publication of WO2012138911A2 publication Critical patent/WO2012138911A2/en
Publication of WO2012138911A3 publication Critical patent/WO2012138911A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention features conjugates of a somatostatin analog and anti-HIV agent (e.g., an HIV protease inhibitor (HPI), such as nelfinavir), and their use in the treatment of a patient (e.g., a human) infected with HIV.
PCT/US2012/032402 2011-04-05 2012-04-05 Conjugates of anti-hiv drugs and somatostatin analogs WO2012138911A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161516581P 2011-04-05 2011-04-05
US61/516,581 2011-04-05

Publications (2)

Publication Number Publication Date
WO2012138911A2 WO2012138911A2 (en) 2012-10-11
WO2012138911A3 true WO2012138911A3 (en) 2012-12-27

Family

ID=46969827

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/032402 WO2012138911A2 (en) 2011-04-05 2012-04-05 Conjugates of anti-hiv drugs and somatostatin analogs

Country Status (1)

Country Link
WO (1) WO2012138911A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6602834B2 (en) 2014-06-30 2019-11-06 ターベダ セラピューティクス インコーポレイテッド Targeted conjugates and particles and formulations thereof
AU2016343817B2 (en) 2015-10-28 2021-05-27 Tva (Abc), Llc SSTR-targeted conjugates and particles and formulations thereof
CA3170367A1 (en) * 2020-03-23 2021-09-30 John M.H. GREGG Anti-viral compounds and methods for administration thereof
WO2022026622A2 (en) * 2020-07-28 2022-02-03 Cytocom Inc. Treatment of viral diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10324700A (en) * 1997-03-28 1998-12-08 Seikagaku Kogyo Co Ltd New anti-hiv conjugate and medicinal composition
US20010029035A1 (en) * 2000-02-14 2001-10-11 Michael Eisenhut Oligonucleotide conjugates
US20060193865A1 (en) * 2002-12-13 2006-08-31 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US20080103094A1 (en) * 2001-05-15 2008-05-01 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of viral infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10324700A (en) * 1997-03-28 1998-12-08 Seikagaku Kogyo Co Ltd New anti-hiv conjugate and medicinal composition
US20010029035A1 (en) * 2000-02-14 2001-10-11 Michael Eisenhut Oligonucleotide conjugates
US20080103094A1 (en) * 2001-05-15 2008-05-01 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of viral infections
US20060193865A1 (en) * 2002-12-13 2006-08-31 Immunomedics, Inc. Camptothecin-binding moiety conjugates

Also Published As

Publication number Publication date
WO2012138911A2 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
PH12015501156A1 (en) Pharmaceutical compositions
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
NZ718708A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
PH12015500115A1 (en) Glucagon analogues
WO2012047856A3 (en) Novel inhibitors of secretion of hepatitis b virus antigens
JO3357B1 (en) Imidazopyrrolidinone compounds
UA105556C2 (en) Combination of compounds comprising hiv integrase inhibitors with other therapeutical agents
MX2019003249A (en) Diagnosis, prevention and treatment of diseases of the joint.
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
EP2841107A4 (en) Cytotoxic-drug delivering molecules targeting hiv (cdm-hs), cytotoxic activity against the human immunodeficiency virus and methods of use
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
MX2017004772A (en) Compositions and methods for physiological delivery using cannabidiol.
GB2498276B (en) Medicinal agent and mode of prevention of HIV contamination, prevention and treatment of diseases caused by HIV and HIV-associated diseases including AIDS.
ES2524385R1 (en) Pharmaceutical composition and its use to prepare a medicine for the treatment and prevention of HIV diseases
MX343505B (en) Methods and compositions for inhibiting hiv transmission.
EP2978449A4 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
BR112014000195A2 (en) darunavir formulations
EA201171186A1 (en) SOKRISTALL ETRAVIRIN AND NICOTINAMIDE
MX347911B (en) Bvdv vaccine.
UA118474C2 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
WO2012138911A3 (en) Conjugates of anti-hiv drugs and somatostatin analogs
GB201014391D0 (en) Drug composition and its use in therapy
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2016002560A (en) Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12768228

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12768228

Country of ref document: EP

Kind code of ref document: A2